Brambilla Roberta, Neary Joseph T, Cattabeni Flaminio, Cottini Lorenzo, D'Ippolito Gianluca, Schiller Paul C, Abbracchio Maria P
Department of Pharmacological Sciences, University of Milan School of Pharmacy, Milan, Italy.
J Neurochem. 2002 Dec;83(6):1285-96. doi: 10.1046/j.1471-4159.2002.01239.x.
The present study has been aimed at characterizing the ATP/P2 receptor (and transductional pathways) responsible for the morphological changes induced in vitro by alphabetamethyleneATP on rat astrocytes obtained from cerebral cortex, a brain area highly involved in neurodegenerative diseases. Exposure of cells to this purine analogue resulted in elongation of cellular processes, an event reproducing in vitro a major hallmark of in vivo reactive gliosis. alphabetamethyleneATP-induced gliosis was prevented by the P2X/P2Y blocker pyridoxalphosphate-6-azophenyl-2'-4'-disulfonic acid, but not by the selective P2X antagonist 2',3'-O-(2,4,6-trinitrophenyl)-ATP, ruling out a role for ligand-gated P2X receptors. Conversely, the Gi/Go protein inactivator pertussis toxin completely prevented alphabetamethyleneATP-induced effects. No effects were induced by alphabetamethyleneATP on intracellular calcium concentrations. RT-PCR and western blot analysis showed that alphabetamethyleneATP-induced gliosis involves up-regulation of cyclooxygenase-2 (but not lipooxygenase). Also this effect was fully prevented by pyridoxalphosphate-6-azophenyl-2'-4'-disulfonic acid. Experiments with inhibitors of mitogen-activated protein kinases (MAPK) suggest that extracellular signal regulated protein kinases (ERK)1/2 mediate both cyclooxygenase-2 induction and the associated in vitro gliosis. These findings suggest that purine-induced gliosis involves the activation of a calcium-independent G-protein-coupled P2Y receptor linked to ERK1/2 and cyclooxygenase-2. Based on the involvement of cyclooxygenase-2 and inflammation in neurodegenerative diseases, these findings open up new avenues in the identification of novel biological targets for the pharmacological manipulation of neurodegeneration.
本研究旨在表征负责α,β-亚甲基ATP在体外对从大脑皮层获取的大鼠星形胶质细胞诱导形态变化的ATP/P2受体(及转导途径),大脑皮层是一个与神经退行性疾病高度相关的脑区。将细胞暴露于这种嘌呤类似物会导致细胞突起伸长,这一事件在体外重现了体内反应性胶质增生的一个主要特征。α,β-亚甲基ATP诱导的胶质增生可被P2X/P2Y阻滞剂磷酸吡哆醛-6-偶氮苯基-2'-4'-二磺酸阻止,但不能被选择性P2X拮抗剂2',3'-O-(2,4,6-三硝基苯基)-ATP阻止,排除了配体门控P2X受体的作用。相反,Gi/Go蛋白失活剂百日咳毒素完全阻止了α,β-亚甲基ATP诱导的效应。α,β-亚甲基ATP对细胞内钙浓度无影响。逆转录聚合酶链反应(RT-PCR)和蛋白质印迹分析表明,α,β-亚甲基ATP诱导的胶质增生涉及环氧化酶-2(而非脂氧合酶)的上调。这种效应也完全被磷酸吡哆醛-6-偶氮苯基-2'-4'-二磺酸阻止。用丝裂原活化蛋白激酶(MAPK)抑制剂进行的实验表明,细胞外信号调节蛋白激酶(ERK)1/2介导环氧化酶-2的诱导及相关的体外胶质增生。这些发现表明,嘌呤诱导的胶质增生涉及与ERK1/2和环氧化酶-2相关的钙非依赖性G蛋白偶联P2Y受体的激活。基于环氧化酶-2和炎症在神经退行性疾病中的作用,这些发现为识别用于神经退行性变药理学操纵的新型生物学靶点开辟了新途径。